Long space missions, gene therapy, and the vital role of magnesium: a three-pronged plan for the next 50 years

William J RoweMedical University of Ohio, Toledo, OH, USAAbstract: Since pharmaceuticals cannot be used in space until liver and kidney dysfunctions are corrected, and with invariable malabsorption, it appears there is no alternative other than to use subcutaneous magnesium (Mg) replacements in the...

Full description

Bibliographic Details
Main Author: William J Rowe
Format: Article
Language:English
Published: Dove Medical Press 2010-09-01
Series:International Journal of Nephrology and Renovascular Disease
Online Access:http://www.dovepress.com/long-space-missions-gene-therapy-and-the-vital-role-of-magnesium-a-thr-a5239
id doaj-c4129c8cc52e40049ee8d56fb4afc516
record_format Article
spelling doaj-c4129c8cc52e40049ee8d56fb4afc5162020-11-25T01:24:58ZengDove Medical PressInternational Journal of Nephrology and Renovascular Disease1178-70582010-09-012010default123127Long space missions, gene therapy, and the vital role of magnesium: a three-pronged plan for the next 50 yearsWilliam J RoweWilliam J RoweMedical University of Ohio, Toledo, OH, USAAbstract: Since pharmaceuticals cannot be used in space until liver and kidney dysfunctions are corrected, and with invariable malabsorption, it appears there is no alternative other than to use subcutaneous magnesium (Mg) replacements in the presence of deficiencies and use of gene therapy. I suggest beginning with the correction of as many as four gene deficiencies: atrial natriuretic peptide (ANP), nitric oxide (NO), vascular endothelial growth factor (VEGF), and erythropoietin (EPO), all as well as Mg related perfusion and angiogenesis. There is no evidence of significant lunar radiation levels in the absence of a solar storm. It could then be determined whether this has resulted in correction of liver and kidney dysfunction. If this persists, serial additions of gene therapy will be required determining the effect of each individual gene trial on organ function. Microgravity and endothelial gaps with leaks trigger reduced plasma volume. Partial correction by use of a plasma volume substitute and development of a delivery device may reduce complexity of gene therapy. Research would be conducted both on Earth and in microgravity, with the development of subcutaneous pharmaceuticals and Mg, and a space walk-reliable subcutaneous silicon device, given that no replenishable subcutaneous device is presently available. A three-pronged approach provides a plan for the next 50 years: A. complete correction of a Mg deficit; B. partial replacement with plasma volume substitutes, and C. multiple gene factor strategy.Keywords: malabsorption, gene therapy, kidneys, liver, magnesium, microgravity, space flight http://www.dovepress.com/long-space-missions-gene-therapy-and-the-vital-role-of-magnesium-a-thr-a5239
collection DOAJ
language English
format Article
sources DOAJ
author William J Rowe
spellingShingle William J Rowe
Long space missions, gene therapy, and the vital role of magnesium: a three-pronged plan for the next 50 years
International Journal of Nephrology and Renovascular Disease
author_facet William J Rowe
author_sort William J Rowe
title Long space missions, gene therapy, and the vital role of magnesium: a three-pronged plan for the next 50 years
title_short Long space missions, gene therapy, and the vital role of magnesium: a three-pronged plan for the next 50 years
title_full Long space missions, gene therapy, and the vital role of magnesium: a three-pronged plan for the next 50 years
title_fullStr Long space missions, gene therapy, and the vital role of magnesium: a three-pronged plan for the next 50 years
title_full_unstemmed Long space missions, gene therapy, and the vital role of magnesium: a three-pronged plan for the next 50 years
title_sort long space missions, gene therapy, and the vital role of magnesium: a three-pronged plan for the next 50 years
publisher Dove Medical Press
series International Journal of Nephrology and Renovascular Disease
issn 1178-7058
publishDate 2010-09-01
description William J RoweMedical University of Ohio, Toledo, OH, USAAbstract: Since pharmaceuticals cannot be used in space until liver and kidney dysfunctions are corrected, and with invariable malabsorption, it appears there is no alternative other than to use subcutaneous magnesium (Mg) replacements in the presence of deficiencies and use of gene therapy. I suggest beginning with the correction of as many as four gene deficiencies: atrial natriuretic peptide (ANP), nitric oxide (NO), vascular endothelial growth factor (VEGF), and erythropoietin (EPO), all as well as Mg related perfusion and angiogenesis. There is no evidence of significant lunar radiation levels in the absence of a solar storm. It could then be determined whether this has resulted in correction of liver and kidney dysfunction. If this persists, serial additions of gene therapy will be required determining the effect of each individual gene trial on organ function. Microgravity and endothelial gaps with leaks trigger reduced plasma volume. Partial correction by use of a plasma volume substitute and development of a delivery device may reduce complexity of gene therapy. Research would be conducted both on Earth and in microgravity, with the development of subcutaneous pharmaceuticals and Mg, and a space walk-reliable subcutaneous silicon device, given that no replenishable subcutaneous device is presently available. A three-pronged approach provides a plan for the next 50 years: A. complete correction of a Mg deficit; B. partial replacement with plasma volume substitutes, and C. multiple gene factor strategy.Keywords: malabsorption, gene therapy, kidneys, liver, magnesium, microgravity, space flight
url http://www.dovepress.com/long-space-missions-gene-therapy-and-the-vital-role-of-magnesium-a-thr-a5239
work_keys_str_mv AT williamjrowe longspacemissionsgenetherapyandthevitalroleofmagnesiumathreeprongedplanforthenext50years
_version_ 1725115975499513856